High Court Stays Mandate In Patent Dispute Over Multiple Sclerosis Drug
WASHINGTON, D.C. — In a miscellaneous order issued Sept. 29, the U.S. Supreme Court halted plans by various drugmakers to launch a generic version of the multiple sclerosis drug Gilenya, in...To view the full article, register now.
Already a subscriber? Click here to view full article